文献速递胸部肿瘤

NLST延长随访:肺癌发病与死亡结果

Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial.
PubMed 文献 · J Thorac Oncol · 2019-06-28

NLST将高危吸烟者随机分组,每年接受低剂量CT或胸片筛查共三次;延长随访中位11.3年(发病)和12.3年(死亡)显示,两组肺癌发病无差异,LDCT组肺癌死亡有下降趋势,预防一例肺癌死亡需筛查303人。

要点

  • 延长随访中LDCT与胸片组肺癌发病无差异(RR=1.01)。
  • 肺癌死亡RR=0.92,稀释校正后RR=0.89。
  • 预防一例肺癌死亡需筛查303人,与原始估计约320相近。

核心结论

  • 延长随访显示LDCT组肺癌死亡风险有下降趋势,但总体死亡率差异未明确。
  • 预防一例肺癌死亡的需筛查人数与原始分析相似。

研究设计与样本

  • 国家肺癌筛查试验(NLST)随机对照研究,高危现吸烟者或既往吸烟者接受三次年度低剂量CT或胸片筛查。
  • 通过链接州癌症登记和国家死亡指数进行延长随访,发病中位随访11.3年,死亡中位随访12.3年。

主要发现

  • LDCT组与胸片组分别诊断肺癌1701例和1681例(RR=1.01,95%CI 0.95-1.09)。
  • 肺癌死亡分别为1147例和1236例(RR=0.92,95%CI 0.85-1.00)。
  • 两组每1000人肺癌死亡差为3.3,需筛查人数为303。
  • 稀释校正后肺癌死亡RR=0.89(95%CI 0.80-0.997)。
  • 总死亡分别为5253例和5366例,每1000人差为4.2(95%CI -2.6至10.9)。

关键数值与推荐

  • 需筛查人数303,与原始估计约320相似。
  • 肺癌死亡RR=0.92(95%CI 0.85-1.00),稀释校正后RR=0.89(95%CI 0.80-0.997)。

临床怎么用

  • 支持在高危吸烟人群中使用LDCT筛查以降低肺癌死亡风险。
  • 延长随访未显示LDCT组肺癌发病总体增加。

局限性

  • 总死亡率差异置信区间宽,不能排除无差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The National Lung Screening Trial (NLST) randomized high-risk current and former smokers to three annual screens with either low-dose computed tomography (LDCT) or chest radiography (CXR) and demonstrated a significant reduction in lung cancer mortality in the LDCT arm after a median of 6.5 years' follow-up. We report on extended follow-up of NLST subjects. METHODS: Subjects were followed by linkage to state cancer registries and the National Death Index. The number needed to screen (NNS) to prevent one lung cancer death was computed as the reciprocal of the difference in the proportion of patients dying of lung cancer across arms. Lung cancer mortality rate ratios (RRs) were computed overall and adjusted for dilution effect, with the latter including only deaths with a corresponding diagnosis close enough to the end of protocol screening. RESULTS: The median follow-up times were 11.3 years for incidence and 12.3 years for mortality. In all, 1701 and 1681 lung cancers were diagnosed in the LDCT and CXR arms, respectively (RR = 1.01, 95% confidence interval [CI]: 0.95-1.09). The observed numbers of lung cancer deaths were 1147 (with LDCT) versus 1236 (with CXR) (RR = 0.92, 95% CI: 0.85-1.00). The difference in the number of patients dying of lung cancer (per 1000) across arms was 3.3, translating into an NNS of 303, which is similar to the original NNS estimate of around 320. The dilution-adjusted lung cancer mortality RR was 0.89 (95% CI: 0.80-0.997). With regard to overall mortality, there were 5253 (with LDCT) and 5366 (with CXR) deaths, for a difference across arms (per 1000) of 4.2 (95% CI: -2.6 to 10.9). CONCLUSION: Extended follow-up of the NLST showed an NNS similar to that of the original analysis. There was no overall increase in lung cancer incidence in the LDCT arm versus in the CXR arm.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial. J Thorac Oncol. 2019. PMID: 31260833. doi:10.1016/j.jtho.2019.05.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。